4 news items
Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
CGTX
21 May 24
product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's Disease
CGTX
22 Apr 24
, the timing and expected results of our clinical trials and any expected or implied benefits or results, including that initial clinical results observed
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
CGTX
26 Mar 24
million for 2022. The increase was primarily related to higher employee compensation and benefits driven by increased headcount and equity-based
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease Studies
CGTX
6 Mar 24
, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812
- Prev
- 1
- Next